RT Journal Article
SR Electronic
T1 Direct Comparison of Antibody Responses to Four SARS-CoV-2 Vaccines in Mongolia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.22.21262161
DO 10.1101/2021.08.22.21262161
A1 Naranjargal J. Dashdorj
A1 Oliver F. Wirz
A1 Katharina Röltgen
A1 Emily Haraguchi
A1 Anthony S. Buzzanco III
A1 Mamdouh Sibai
A1 Hannah Wang
A1 Jacob A. Miller
A1 Daniel Solis
A1 Malaya K. Sahoo
A1 Sumiya Byambabaatar
A1 Purevjargal Bat-Ulzii
A1 Anir Enkhbat
A1 Enkhtuul Batbold
A1 Delgersaikhan Zulkhuu
A1 Byambasuren Ochirsum
A1 Tungalag Khurelsukh
A1 Ganbold Dalantai
A1 Natsagdorj Burged
A1 Uurtsaikh Baatarsuren
A1 Nomin Ariungerel
A1 Odgerel Oidovsambuu
A1 Andreas S. Bungert
A1 Zulkhuu Genden
A1 Dahgwahdorj Yagaanbuyant
A1 Altankhuu Mordorj
A1 Theodore Jardetzky
A1 James L. Wilbur
A1 Jacob N. Wohlstadter
A1 George B. Sigal
A1 Benjamin A. Pinsky
A1 Scott D. Boyd
A1 Naranbaatar D. Dashdorj
YR 2021
UL http://medrxiv.org/content/early/2021/08/28/2021.08.22.21262161.abstract
AB Different vaccines for SARS-CoV-2 are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four Covid vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant RBD proteins reveal marked differences in the vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control the COVID-19 pandemic in Mongolia and worldwide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by NIH/NIAID HHSN272201700013C (GBS); NIH/NIAID R01AI127877 (SDB), NIH/NIAID R01AI130398 (SDB), NIH 1U54CA260517 (SDB, BAP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent for research participation and collection of blood and nasopharyngeal swab specimens was obtained, with research volunteers signing a consent form approved by the Ethics Review Board at the Ministry of Health of Mongolia.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data are available upon request.